

## Special Issue

# Melatonin in Psychiatric Disorders

### Message from the Guest Editor

Psychiatric disorders constitute a growing health burden worldwide. Melatonin has attracted particular interest due to the potential role as an aetiological factor in some disorders (e.g., bipolar disorder due to alteration in circadian rhythms). Melatonin agonists, such as agomelatine, have been approved for the treatment of major depression, while others may be of utility in the treatment of sleep disturbance associated with psychiatric disorders. Alteration of the sensitivity of melatonin to light and the daily secretion of the hormone have been proposed as biomarkers in some disorders. Melatonin itself has been proposed as a treatment for seasonal affective disorders as well as the metabolic syndrome associated with the use of atypical antipsychotic medications. The aetiological significance of melatonin secretion and rhythm alterations remains debatable, while the therapeutic effects, at least of the agonists, have a better evidence base. This Special Issue aims to identify and review data related to melatonin secretion, rhythms and the use of agonists in psychiatric disorders.

### Guest Editor

Dr. Trevor Norman

Department of Psychiatry, The University of Melbourne, Austin Hospital, Heidelberg 3084, Australia

### Deadline for manuscript submissions

closed (30 June 2019)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/21700](https://mdpi.com/si/21700)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).